PR3-AAV Resilient Remission Or PRRR
Rochester, MN
The purpose of this study is to determine the proportion of patients achieving both complete remission and seronegativity for Anti-Neutrophil Cytoplasmic Antibody (ANCA) at 6 months.
The study is a double-blind, randomized, active controlled phase 2 study. It will take place at multiple sites and enroll 30 patients who have clinical diagnosis of either granulomatosis with polyangiitis or microscopic polyangiitis (PR3-AAV). It will look at the study drug, Obinutuzumab, for the treatment of these diagnosis and evaulate the safety of the drug. Subjects will be followed for 18 months after first treatment. The study will complete when all enrolled subjects are have been ...